Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
复制标题
软组织肉瘤免疫治疗的事实与希望。
DOI：
10.1158/1078-0432.ccr-19-3335
复制
发表时间：
2020-11-15
期刊：
影响因子：
--
通讯作者：
Van Tine BA
中科院分区：
文献类型：
--
作者：
Martín-Broto J;Moura DS;Van Tine BA
肉瘤是间叶性肿瘤，包括超过175种亚型，每一种都有自己的遗传复杂性。因此，免疫治疗方法在广泛的不同亚型中并没有普遍成功。在软组织肉瘤（STS）中使用免疫疗法的科学的实际状态和当前的临床数据将在这篇综述中详细介绍。更确切地说，综述将集中在：a）免疫微环境在新治疗方法的开发和活性中的作用; B）肉瘤免疫类（SIC）组的最新鉴定，特别是SIC E组及其预测免疫治疗反应的B细胞特征; c）使用PD-1和/或CTLA-4抑制剂的临床试验，其用作响应数据的参考，d）来自抗血管生成剂与PD-1抑制剂的组合的有前景的临床活性E）靶向NY-ESO或MAGEA 4的用于滑膜肉瘤的适应性T细胞疗法;和F）使用病毒疗法T-VEC与PD-1抑制剂进行局部治疗的作用。在这里，我们提出了肉瘤患者的事实和希望，因为该领域正在迅速推进其对使用各种类型的免疫疗法的理解。
Sarcomas are mesenchymal tumors, encompassing more than 175 subtypes, each one with their own genetic complexities. As a result, immunotherapy approaches have not been universally successful across the wide rage of diverse subtypes. The actual state of science and the current clinical data utilizing immunotherapy within the soft tissue sarcomas (STS) will be detailed in this review. More precisely, the review will focus on: a) the role of the immune microenvironment in the development and activity of new therapeutic approaches; b) the recent identification of the sarcoma immune class (SIC) groups, especially group SIC E with its B cell signature that predicts immunotherapy response; c) the clinical trials using PD-1 and/or CTLA-4 inhibitors, which serves as reference for response data, d) the promising clinical activity from the combination of anti-angiogenics agents with PD-1 inhibitors E) the adapted T-cell therapies for synovial sarcoma that target either NY-ESO or MAGEA4; and F) the role for localized therapy using the virotherapy T-VEC with PD-1 inhibitors. Herein we present the facts and the hopes for the sarcoma patients, as the field is rapidly advancing its understanding of what and where to use the various types of immunotherapies.